Serum Levels of Calcification Inhibitors in Patients With Intracerebral Hemorrhage

REFERENCES

• Towfighi A, Ovbiagele B, Saver JL. Therapeutic milestone: stroke declines from the second to the third leading organ and disease-specific cause of death in the United States. Stroke. 2010;41:499–503.
   PubMedGoogle Scholar
• Brown RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke. 1996;27:373–80.
   PubMedGoogle Scholar
• Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. Lancet. 2009;373:1632–44.
   PubMedGoogle Scholar
• Shanahan CM, Cary NR, Salisbury JR, Proudfoot D, Weissberg PL, Edmonds ME. Medial localization of mineralization-regulating proteins in association with Mönckeberg's sclerosis: evidence for smooth muscle cell-mediated vascular calcification. Circulation. 1999;100:2168–76.
   PubMedGoogle Scholar
• Vinters HV, Natte R, Maat-Schieman ML, van Duinen SG, Hegeman-Kleinn I, Welling-Graafland C, Haan J, Roos RA. Secondary microvascular degeneration in amyloid angiopathy of patients with hereditary cerebral hemorrhage with amyloidosis, Dutch type (HCHWA-D). Acta Neuropathol (Berl). 1998;95: 235–44.
   PubMedGoogle Scholar
• Mazzini MJ, Schulze PC. Proatherogenic pathways leading to vascular calcification. Eur J Radiol. 2006;57:384–89
   Google Scholar
• Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M, Shlipak MG, Whooley MA, Ix JH. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease. The Heart and Soul Study. Ann Intern Med. 2010;152:640–8.
   PubMedGoogle Scholar
• Wang AY, Woo J, Lam CW, Wang M, Chan IH, Gao P, Lui SF, Li PK, Sanderson JE. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant. 2005;20:1676–85.
   PubMedGoogle Scholar
• Mendioroz M, Fernández-Cadenas I, Rosell A, Delgado P, Domingues-Montanari S, Ribó M, Penalba A, Quintana M, Alvarez-Sab'n J, Montaner J. Osteopontin predicts long-term functional outcome among ischemic stroke patients. J Neurol. 2011;258:486–93.
   PubMedGoogle Scholar
• Metry G, Stenvinkel P, Qureshi AR, Carrero JJ, Yilmaz MI, Bárány P, Snaedal S, Heimbürger O, Lindholm B, Suliman ME. Low serum fetuin-A concentration predicts poor outcome only in the presence of inflammation in prevalent haemodialysis patients. Eur J Clin Invest. 2008;38:804–11.
   PubMedGoogle Scholar
• Wang J, Doré S. Inflammation after intracerebral hemorrhage. J Cereb Blood Flow Metab. 2007;27:894–908.
   PubMedGoogle Scholar
• Hemphill JC, Farrant M, Neill TA. Prospective validation of the ICH Score for 12-month functional outcome. Neurology. 2009;73:1088–94.
   PubMedGoogle Scholar
• Bugnicourt JM, Chillon JM, Massy ZA, Canaple S, Lamy C, Deramond H, Godefroy O. High prevalence of intracranial artery calcification in CKD: a retrospective study. Clin J Am Soc Nephrol. 2009;4:284–90.
   PubMedGoogle Scholar
• Bugnicourt JM, Chillon JM, Tribouilloy C, Canaple S, Lamy C, Massy ZA, Godefroy O. Relation between intracranial artery calcifications and aortic atherosclerosis in ischemic stroke patients. J Neurol. 2010;257:1338–43.
   PubMedGoogle Scholar
• Kothari RU, Brott T, Broderick JP, Barsan WG, Sauerbeck LR, Zuccarello M, Khoury J. The ABCs of measuring intracerebral hemorrhage volumes. Stroke. 1996;27:1304-5.
   PubMedGoogle Scholar
• Vemmos KN, Tsivgoulis G, Spengos K, Papamichael CM, Cimboneriu A, Zis V, Zakopoulos N, Mavrikakis M. Common carotid artery intima-media thickness in patients with brain infarction and intracerebral haemorrhage. Cerebrovasc Dis. 2004;17:280–6.
   PubMedGoogle Scholar
• Pleşea IE, Cameniţă A, Georgescu CC, Enache SD, Zaharia B, Georgescu CV, Tenovici M. Study of cerebral vascular structures in hypertensive intracerebral haemorrhage. Rom J Morphol Embryol. 2005;46:249–56.
   PubMedGoogle Scholar
• Strand M, Soderstrom I, Wiklund PG, Hallmans G, Weinehall L, Soderberg S, Olsson T. Polymorphisms at the osteoprotegerin and interleukin-6 genes in relation to first-ever stroke. Cerebrovasc Dis. 2007;24:418–25.
   PubMedGoogle Scholar
• Speer MY, McKee MD, Guldberg RE, Liaw L, Yang HY, Tung E, Karsenty G, Giachelli CM. Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med. 2002;196:1047–55.
   PubMedGoogle Scholar
• Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W. The serum protein alpha-2-Heremans–Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest. 2003;112:357–66.
   PubMedGoogle Scholar
• Schlieper G, Westenfeld R, Brandenburg V, Ketteler M. Inhibitors of calcification in blood and urine. Semin Dial. 2007;20:113–21.
   PubMedGoogle Scholar
• Jono S, Ikari Y, Vermeer C, Dissel P, Hasegawa K, Shioi A, Taniwaki H, Kizu A, Nishizawa Y, Saito S. Matrix Gla protein is associated with coronary artery calcification as assessed by electron-beam computed tomography. Thromb Haemost. 2004;91:790–94.
   Google Scholar
• del Río-Espínola A, Fernández-Cadenas I, Rubiera M, Quintana M, Domingues-Montanari S, Mendióroz M, Fernández-Morales J, Giralt D, Molina CA, Alvarez-Sab'n J, Montaner J. CD40-1C>T polymorphism (rs1883832) is associated with brain vessel reocclusion after fibrinolysis in ischemic stroke. Pharmacogenomics. 2010;11:763–72.
   PubMedGoogle Scholar
• Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386:78–81.
   PubMedGoogle Scholar
• Shea MK, O'Donnell CJ, Vermeer C, Magdeleyns EJ, Crosier MD, Gundberg CM, Ordovas JM, Kritchevsky SB, Booth SL. Circulating uncarboxylated matrix gla protein is associated with vitamin K nutritional status, but not coronary artery calcium, in older adults. J Nutr. 2011;141:1529–34.
   PubMedGoogle Scholar
• Wang H, Li W, Zhu S, Li J, D'Amore J, Ward MF, Yang H, Wu R, Jahnen-Dechent W, Tracey KJ, Wang P, Sama AE. Peripheral administration of fetuin-A attenuates early cerebral ischemic injury in rats. J Cereb Blood Flow Metab. 2010;30:493–504.
   PubMedGoogle Scholar
• Westenfeld R, Schäfer C, Smeets R, Brandenburg VM, Floege J, Ketteler M, Jahnen-Dechent W, . Fetuin-A (AHSG) prevents extraosseous calcification induced by uraemia and phosphate challenge in mice. Nephrol Dial Transplant. 2007;22:1537–46.
   PubMedGoogle Scholar
• Roos M, Oikonomou D, von Eynatten M, Luppa PB, Heemann U, Lutz J, Baumann M, Nawroth PP, Bierhaus A, Humpert PM. Associations of Fetuin-A levels with vascular disease in type 2 diabetes patients with early diabetic nephropathy. Cardiovasc Diabetol. 2010;9:48–55.
   Google Scholar
• Ketteler M, Bongartz P, Westenfeld R. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003;361:827–33.
   PubMedGoogle Scholar
• Stenvinkel P, Wang K, Qureshi AR, Luppa PB, Heemann U, Lutz J, Baumann M, Nawroth PP, Bierhaus A, Humpert PM. Low fetuin-A levels are associated with cardiovascular death: impact of variations of gene encoding fetuin. Kidney Int. 2005;67:2283–92.
   Google Scholar
• Tuttolomondo A, Di Raimondo D, Di Sciacca R, Casuccio A, Bivona G, Bellia C, Barreca L, Serio A, D'Aguanno G, Ciaccio M, Licata G, Pinto A. Fetuin-A and CD40 L plasma levels in acute ischemic stroke: differences in relation to TOAST subtype and correlation with clinical and laboratory variables. Atherosclerosis. 2010;208:290–6.
   PubMedGoogle Scholar
• Weikert C, Stefan N, Schulze MB, Pischon T, Berger K, Joost HG, Häring HU, Boeing H, Fritsche A. Plasma fetuin-A levels and the risk of myocardial infarction and ischemic stroke. Circulation. 2008;118:2555–62.
   PubMedGoogle Scholar
• Weber GF, Zawaideh S, Hikita S, Kumar VA, Cantor H, Ashkar S. Phosphorylation dependent interaction of osteopontin with its receptors regulates macrophage migration and activation. J Leukoc Biol. 2002;72:752–58.
   Google Scholar
• Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol. 2007;27:2302–9.
   PubMedGoogle Scholar
• Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest. 1993;92:1686–96.
   PubMedGoogle Scholar
• Chowdhury SA, Lin J, Sadiq SA. Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis. Arch. Neurol. 2008;65: 232–35.
   Google Scholar
• Wu B, Ma Q, Suzuki H, Chen C, Liu W, Tang J, Zhang J. Recombinant osteopontin attenuates brain injury after intracerebral hemorrhage in mice. Neurocrit Care. 2011;14:109–17.
   PubMedGoogle Scholar
• Scott JA, Weir ML, Wilson SM, Xuan JW, Chambers AF, McCormack DG. Osteopontin inhibits inducible nitric oxide synthase activity in rat vascular tissue. Am J Physiol. 1998;275:2258–65.
   Google Scholar